Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Mpm Bioimpact Llc
Form 13F · Q2 2026

Mpm Bioimpact Llc

CIK 1687078Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$1.6B
Reported book value
37
Positions
12
Quarters on record
Top 50
Positions

Mpm Bioimpact Llc — holdings

Top 37 positions of 37, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1CGEM Cullinan Therapeutics Inc9.7M+27.2%$177M10.8%
2AKTS Aktis Oncology Inc4.8M+0.0%$156M9.5%
3LQDA Liquidia Corporation1.4M−1.4%$111M6.7%
4RVMD Revolution Medicines Inc492,483−2.8%$92M5.6%
5CORT Corcept Therapeutics Inc771,028−21.8%$67M4.1%
6EWTX Edgewise Therapeutics Inc1.6M−2.4%$66M4.0%
7TVTX Travere Therapeutics Inc1.1M−0.9%$64M3.9%
8DBVT Dbv Technologies S A3.7M−29.7%$60M3.7%
9TRVI Trevi Therapeutics Inc3.1M−6.8%$57M3.5%
10ALMS Alumis Inc2.0M−15.4%$57M3.5%
11QURE Uniqure Nv1.2M−10.5%$56M3.4%
12RARE Ultragenyx Pharmaceutical In1.4M—$47M2.9%
13RLAY Relay Therapeutics Inc2.4M+2.4%$45M2.8%
14ABVX Abivax Sa336,347+213.6%$45M2.7%
15DYN Dyne Therapeutics Inc1.9M+36.5%$43M2.6%
16DNTH Dianthus Therapeutics Inc420,002−0.9%$41M2.5%
17BIOA Bioage Labs Inc1.7M—$41M2.5%
18URGN Urogen Pharma Ltd933,415−1.1%$34M2.1%
19MLTX Moonlake Immunotherapeutics1.6M−11.3%$31M1.9%
20PVLA Palvella Therapeutics Inc Ne204,027−1.2%$31M1.9%
21TSHA Taysha Gene Therapies Inc4.5M—$31M1.9%
22SNDX Syndax Pharmaceuticals Inc1.3M−0.5%$29M1.8%
23GLUE Monte Rosa Therapeutics Inc1.2M−1.3%$28M1.7%
24ZURA Zura Bio Ltd4.5M—$26M1.6%
25NTRA Natera Inc92,638−0.5%$25M1.5%
26STOK Stoke Therapeutics Inc723,314−5.7%$24M1.4%
27ANL Adlai Nortye Ltd1.9M—$22M1.4%
28BLTE Belite Bio Inc137,208+55.8%$21M1.3%
29FORTE BIOSCIENCES INC Forte Biosciences Inc987,448−1.3%$21M1.3%
30ORIC Oric Pharmaceuticals Inc1.9M+4.3%$20M1.2%
31TARS Tarsus Pharmaceuticals Inc322,007−2.3%$20M1.2%
32ANNX Annexon Inc3.5M—$20M1.2%
33DRUG Bright Minds Biosciences Inc202,114−4.7%$14M0.9%
34TRDA Entrada Therapeutics Inc1.3M—$9M0.6%
35ACRS Aclaris Therapeutics Inc1.0M+166.0%$6M0.3%
36CNTX Context Therapeutics Inc1.3M−87.8%$719,5420.0%
37HOWL Werewolf Therapeutics Inc80,142−93.4%$28,8510.0%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.